EHA 2024 | Real-world experience of the use of brexu-cel in patients with B-ALL and less than 5% marrow blasts
Nitin Jain, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, shares data from a real-world experience of brexucabtagene autoleucel (brexu-cel) treatment in adults with relapsed/refractory (R/R) B-cell acute lymphoblastic leukemia (B-ALL) with less than 5% marrow blasts. Brexu-cel had a favorable toxicity profile, with very few high-grade cases of cytokine release syndrome (CRS) or immune effector cell-associated neurotoxicity syndrome (ICANS). Even in patients with undetectable levels of measurable residual disease (MRD) prior to therapy, significant CAR T-cell expansion was observed. However, Dr Jain highlights that further follow-up is needed before conclusions can be drawn regarding the real-world efficacy of brexu-cel. This interview took place at the 29th Congress of the European Hematology Association (EHA) in Madrid, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
